<DOC>
	<DOCNO>NCT02630836</DOCNO>
	<brief_summary>Prospective , unicenter , randomize , open-label , single-dose , two-arms blind assessor pilot study . Thirty-two ( 32 ) elderly patient hip fracture randomize one two treatment-arms ( Xcel-MT-osteo-beta Standard treatment ) follow 12 month primary objective safety . Secondary objective efficacy axial tomography xRay , clinical efficacy quality life questionnaire .</brief_summary>
	<brief_title>Allogeneic Mesenchymal Stromal Cells Elderly Patients With Hip Fracture</brief_title>
	<detailed_description>Prospective , unicenter , randomize , open-label , single-dose , two-arms blind assessor phase I-II pilot study . Thirty-two ( 32 ) elderly patient ( 70-85 year age ) type 31A2 31A3 fracture femur ( AO/ASIF ( Association Study Internal Fixation ) classification ) admit emergency room Hospital Clinic Barcelona randomize 1:1 one two treatment-arms ( endomedullary nailing + XCEL-MT-OSTEO-BETA isolate endomedullary nailing standard treatment ) . Once surgically treat , patient follow 12 month primary objective safety . Secondary objective efficacy axial tomography xRay , clinical efficacy quality life questionnaire ( EUROQOL-5D ) .</detailed_description>
	<mesh_term>Fractures , Bone</mesh_term>
	<mesh_term>Femoral Neck Fractures</mesh_term>
	<criteria>1 . Patient between70 85 year old 2 . Proximal femur fracture type 31A3 31a2 classification AO/ASIF . 3 . Deambulation prior fracture . 4 . Written informed consent patient family member . 1 . Presence implant proximal femur level . 2 . Presence local systemic septic process . 3 . Septic arthritis . 4 . Dementia type . 5 . Hematological biochemical analysis significant alteration contraindicate surgery . 6 . Patients positive serology HIV 1 2 , Hepatitis B , Hepatitis C syphilis . 7 . Neoplastic disease detect last five year without complete remission . 8 . Immunosuppressive status . 9 . Patients receive corticosteroid 3 month prior study initiation . 10 . Simultaneous participation another clinical trial treatment another investigational product within 3 month prior inclusion study . 11 . Other condition circumstance may compromise patient 's participation study accord medical criterion . 12 . Patient refusal follow period may exceed clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>mesenchymal stromal cell</keyword>
	<keyword>stem cell</keyword>
	<keyword>elderly</keyword>
	<keyword>allogeneic</keyword>
	<keyword>bone marrow</keyword>
	<keyword>bone regeneration</keyword>
	<keyword>fracture</keyword>
</DOC>